An interventional study of Pharmacogenetics Testing in Pharmacogenetic Testing to Determine Pharmacological Treatment in PTSD, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Not applicable, Interventional, and Treatment
Among 125 studies in Stress Disorders, Post-Traumatic with a site in Canada — 32 open to participants now, 40 under way, 2 of them phase 3. Stress Disorders, Post-Traumatic · Canada.
Among the 125 studies in Stress Disorders, Post-Traumatic with a site in Canada, this one is the 13th largest by planned enrollment of the 111 interventional ones that give a count, is one of 7 that started in 2024, is one of 82 with no phase, reaches primary completion later than 23 of the 39 other live ones, and was the 104th registered.
2,682 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 601 are open to participants now.
This study's planned enrollment of 155 is above the median of 69 across 2,196 interventional studies indexed under Stress Disorders, Post-Traumatic.
Browse Stress Disorders, Post-Traumatic studies →32 of the 125 studies in Stress Disorders, Post-Traumatic with a site in Canada are open now, in 2 countries. Each count lists the studies.
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 186 (45%) set no upper age limit and 205 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →125 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 7 started in 2024.
Median enrollment 54 across the 111 interventional studies, 303 across the 14 observational. Of the 65 that completed or were terminated, 6 (9%) have results posted.
15 of 125 have an industry lead sponsor. The 10 most frequent:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 331 studies on the registry; 137 are open to participants now.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's has 8 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
8 of the studies in Stress Disorders, Post-Traumatic with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06705296Sunnybrook Health Sciences CentreDeep Brain Stimulation for Refractory PTSD | 2026-11-01 |
| NCT07137845Université de SherbrookeVirtual Reality and Cranial Nerve Non-invasive Neuromodulation to Improve Quality of Life for Veterans | 2026-12 |
| NCT07309302Université du Québec a MontréalPsychosocial Factors and Efficacy of Remote Cognitive Remediation for Post-Traumatic Stress Disorder | 2026-12 |
| NCT07146633Centre for Addiction and Mental HealthEfficacy of an EMDR App for PTSD and SUD | 2027-01-30 |
| NCT06044675RemedyMDMA-Assisted CBCT for PTSD vs CBCT RCT | 2027-03-31 |
Among the 125 studies in Stress Disorders, Post-Traumatic with a site in Canada, from their registry updates:
This study is an observational clinical trial aimed at to evaluate the use of pharmacogenetic testing (PGx) for mental health treatment in members and Veterans of the CAF and RCMP patient population as well as the attitudes of both St. Joseph's OSI Clinic Psychiatrists and patients towards PGx. Both OSI Clinic Psychiatrists participants and patient participants will be administered a brief demographic survey in addition to a survey examining their views on, and current knowledge of PGx. Patient participants will have an opportunity to opt-in to or opt-out of receiving PGx. For patient participants who opt-in to PGx (PGx-guided treatment group), a report summarizing the PGx results will be sent to each patient participants' respective OSI Clinic Psychiatrist, alongside a questionnaire that captures the OSI Clinic Psychiatrist participant's treatment planning and changes to treatment planning. Where applicable, past treatment data from patient participants acquired at the St. Joseph's OSI Clinic will be used to identify the number of prior medication changes. Patient participants who opt-out of PGx but continue to receive pharmacologic care at the St. Joseph's OSI Clinic will act as a standard care comparator treatment group. Patient participant's outcomes including PTSD, depression and anxiety severity, and medication-related side effects, will be assessed until the patient participant is discharged from the OSI Clinic or after 24 weeks, whichever comes first. All patient participants, regardless of their study treatment group, will have their symptomatology collected via standard care data collection protocol (Client Reported Outcomes Monitoring Information System (CROMIS) and electronic medical records (EMR)); a self-report assessing the presence of side effects will be completed via Lawson REDCap. OSI Clinic Psychiatrist participants and patient participants will be asked to complete a virtual exit interview at the end of their participation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Provider participant:
Currently working as an OSI Clinic Psychiatrist at the London St. Joseph's OSI Clinic.
Patient participant:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mental health provider's thoughts on pharmacogenetic testing for treatment planning and changes to treatment planning.
For patient participants who opt-in to pharmacogenetic testing, a report summarizing the pharmacogenetic testing results will be sent to each patient participants' respective mental health provider.
Genetic: Pharmacogenetics Testing
For patient participants who opt-out to pharmacogenetic testing will be followed to see if treatment course is maintained.
Genetic test to determine individual genetic compatibility with multiple pharmaceutical drug classes to determine best outcomes for prescription drug treatment.
PHQ-9 - Patient Health Questionnaire 9
Objectifies degree of depression severity
Time frame: 5 minutes
GAD-7 - General Anxiety Disorder-7
Measures severity of anxiety
Time frame: 5 minutes
PCL-5 - Posttraumatic Stress Disorder Checklist - 5
A 20-item self-report tool that corresponds to the 20 symptoms listed in the DSM-V
Time frame: 5 minutes
OQ-45 - Outcome Questionnaire 45
A 45-item multiple-choice self-report inventory used to measure psychotherapy progress in adult patients
Time frame: 10 minutes
Pharmacological Side Effect Measure
To determine if the participant is experiencing any new or worsening or continuing side effects related to prescription medications
Time frame: 10 minutes
Electronic Medical Record Extraction Measure
To determine trial and error attempts with pharmacological prescriptions in an attempt to minimize and/or control symptoms
Time frame: 10 minutes
Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.
Of 1,064 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 36 months is close to that.
Counting every sponsor, half of 1,092 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's →